AUA 2025 – J&J scores in a new bladder cancer use
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
ImmunityBio follows through in lung cancer
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
Protara could take on J&J
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
J&J ramps up its bladder cancer battle
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
